VESALIUS-CV will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.
MAIN RESULTS:
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
N Engl J Med. 2026 Jan 8;394(2):117-127.
VESALIUS-CV on ClinicalTrials.gov
PRIMARY RESULTS PRESENTATION
OTHER PRESENTATIONS
Evolocumab in Patients without Known Atherosclerosis and with Diabetes-Secondary Analysis from VESALIUS-CV (Marston, ACC 2026)
Evolocumab in patients with prior percutaneous coronary intervention and no prior MI-Results from the VESALIUS-CV trial (Bergmark, EuroPCR 2026)